

## Special Issue

# Novel Vaccine Approaches for Emerging RNA Viruses

### Message from the Guest Editor

Emerging RNA viruses continue to pose a unique threat to global human health. This special issue seeks manuscripts that evaluate new approaches to develop vaccine technology in the field of emerging RNA viruses. These approaches can include basic proof-of-concept approaches for vaccine development, novel adjuvant approaches, immunology of vaccine approaches, and translational efforts to evaluate immunogenicity and efficacy of a vaccine approach for emerging RNA viruses. We are particularly interested in manuscripts that evaluate novel platforms for rapid vaccine development. A continued and persistent effort to develop novel vaccine candidates and approaches for a variety of RNA viruses will provide an important pipeline of data as new RNA viruses emerge and threaten global human health in the future.

---

### Guest Editor

Dr. David Beckham

Division of Infectious Diseases, Departments of Medicine and Immunology & Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA

---

### Deadline for manuscript submissions

closed (31 May 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/63142](https://mdpi.com/si/63142)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).